

**CURRICULUM VITAE**

**First name**                    **Francesco**  
**Surname**                      **Bertoni**  
**Date of birth**                 August 5th, 1969  
**Place of birth**                Rome, Italy  
**Citizenship**                 Italian  
**Marital status**                Married, two daughters  
**Work address**                Lymphoma Genomics Group, head  
                                       Institute of Oncology Research, deputy director,  
                                       Faculty of Biomedical Sciences, Universita' della Svizzera italiana (USI)  
                                       via Francesco Chiesa 5, 6500 Bellinzona Switzerland  
**phone**                         +41 58 666 72 06  
**E-mail**                         frbertoni@mac.com, francesco.bertoni@ior.usi.ch  
**ORCID**                         <https://orcid.org/0000-0001-5637-8983>  
**Link to updated and full publications list**    <https://www.dropbox.com/s/4mvdfunv5kkcau6/pubs.pdf?dl=0>

**EDUCATIONAL BACKGROUND**

July 26<sup>th</sup>, 1994                    Medical Doctor, summa cum laude, State University of Milan, Italy, with degree thesis "*Linfomi non Hodgkin a grado intermedio-alto di malignità: strategie terapeutiche ed esperienza presso l'Istituto San Raffaele*"

**SPECIALITY BOARD**

November 10<sup>th</sup>, 1998            Post-graduated in Oncology summa cum laude, Specialty School of Oncology, State University of Milan, Italy, with degree thesis "*Analisi molecolare del riarrangiamento genico delle catene pesanti delle immunoglobuline nel linfoma primitivo gastrico a cellule B della zona marginale (di tipo MALT)*" (Milan, November 10<sup>th</sup>, 1998)

**ADDITIONAL EDUCATION AND QUALIFICATIONS**

November, 2021                GCP Sponsor-Investigator level, CTU-EOC, Lugano, Switzerland  
 October, 2021                 GCP Investigator level, CTU-EOC, Lugano, Switzerland  
 Since 2/2019                 Adjunct Professor, Faculty of Biomedical Sciences, Universita' della Svizzera italiana (USI), Lugano, Switzerland  
 Since 7/2017                 Italian "Abilitazione Scientifica Nazionale alle funzioni di Professore Universitario di Prima Fascia", Bando D.D. 1532/2016, Settore Concorsuale 06/D3 "Malattie del Sangue, Oncologia e Reumatologia" (20/7/2017-20/7/2029)  
 June, 2015                    FELASA Category B LTK module 1, University of Zurich, Zurich, Switzerland

**RESEARCH TOPICS**

Development of anti-lymphoma compounds  
 Lymphoma genomics

**WORKING EXPERIENCES**

**Since 3/2020**                Research Consultant, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland  
**Since 9/2011**                Group Leader of the Lymphoma Genomics Group; Head of the Lymphoma and Genomics Research Program; Deputy Director of the Institute of Oncology Research, Bellinzona, Switzerland  
 4/2007- 9/2011                Deputy Director of Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland

3/2003- 9/2011	Head of the Functional Genomics, Lymphoma Unit, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland
10/1999 – 2/2003	Department of Experimental Haematology (Finbarr E. Cotter), The Barts and The London - Queen Mary's School of Medicine and Dentistry, London, UK
4-9/1999	Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (Franco Cavalli), c/o Ospedale Regionale, Locarno, Switzerland
4/1998-3/ 1999	Molecular Pharmacology Unit (Massimo Brogгинi), Department of Oncology (Maurizio D'Incalci), "Mario Negri" Institute of Pharmacological Research, Milan, Italy
1-4/1998	Molecular Haematology Unit (Finbarr E. Cotter), Institute of Child Health, University College London Medical School, London, United Kingdom
1/1996-12/1997	Medical Oncology Department and Bone Marrow Transplantation Laboratory (Emanuele Zucca), Servizio Oncologico Cantonale (Franco Cavalli), Ospedale Regionale, Locarno, Switzerland
8/1995	Medical Oncology Department, Servizio Oncologico Cantonale (Franco Cavalli), Ospedale San Giovanni, Bellinzona, Switzerland
2-12/1995	Service of Medical Oncology (Paolo Foa) at the 1st Postgraduate School of Haematology (Anna Teresa Maiolo), State University, Ospedale Maggiore, Milan, Italy
11/1991-1/1995	Division of Medicine II (Claudio Rugarli), Istituto Scientifico San Raffaele, Milan, Italy

## **ADDITIONAL RESPONSIBILITIES**

### On-going

Since 9/2024	Member of the Academic Advisory Committee of the Regional Alliance of Lymphoma Subspecialty for Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Since 2/2024	Ex officio member of the SIB Swiss Institute of Bioinformatics Foundation Council
Since 12/2022	Core Team Member, Project Group Developmental Therapeutics of the Swiss Group for Clinical Cancer Research (SAKK)
Since 6/2022	Member of the USI Startup Centre Scientific Board
Since 1/2008	Editor-in-Chief, Hematological Oncology
Since 1/2022	Member of the Scientific Committee of the Swiss Cancer League and Swiss Cancer Research foundation
Since 1/2022	Member of the Editorial Board, Annals of Lymphoma.
Since 1/2022	Mentor, College of the European School of Oncology (ESCO)
Since 6/2021	Member of the Scientific Advisory Board of the Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
Since 2021	Chairman, Organizing Committee, International Conference on Malignant Lymphoma (17-ICML)
Since 8/2020	Associate-Editor, Exploration of Targeted Anti-tumor Therapy
Since 10/2018	Ambassador of the European Association for Cancer Research
Since 12/2013	Member of the Editorial Board, Cancer Biology & Medicine

### Past

1/2022-3/2025	President, Project Group Lymphoma of the Swiss Group for Clinical Cancer Research (SAKK)
2024	Co-chair of the Scientific Program Committee of the 4 <sup>th</sup> AACR International Meeting "Advances in Malignant Lymphoma"
2022	Co-chair of the Scientific Program Committee of the 3 <sup>rd</sup> AACR International Meeting "Advances in Malignant Lymphoma"
2020	Co-chair of the Scientific Program Committee of the 2 <sup>nd</sup> AACR International Meeting "Advances in Malignant Lymphoma"
6/2016-12/2021	Vice-president of the Project Group Lymphoma of the Swiss Group for Clinical Cancer Research (SAKK)
1/2020-3/2022	Member of the Editorial Board, Cancers
2/2020-3/2022	Member of the Editorial Board, Clinical Epigenetics
2012-2019	Authorized Thesis Director, UNIL Université de Lausanne, Lausanne, Switzerland

2019-2021	President, Organizing Committee, 16 <sup>th</sup> International Conference on Malignant Lymphoma (16-ICML)
2018	Co-chair of the Scientific Program Committee of the 1 <sup>st</sup> AACR International Meeting “Advances in Malignant Lymphoma”
2017-2019	Member of the Organizing Committee, 15 <sup>th</sup> International Conference on Malignant Lymphoma (15-ICML)
2015-2017	Member of the Organizing Committee, 14 <sup>th</sup> International Conference on Malignant Lymphoma (14-ICML)
2013-2015	Member of the Organizing Committee, 13 <sup>th</sup> International Conference on Malignant Lymphoma (13-ICML)
2013-2014	Lymphoma co-Editor, Elsevier Ltd website “Leukaemia & Lymphoma”
2011-2013	Member of the Organizing Committee, 12 <sup>th</sup> International Conference on Malignant Lymphoma (12-ICML)
2009-2011	Member of the Advisory Board, 11 <sup>th</sup> International Conference on Malignant Lymphoma (11-ICML)
6/2007-04/2023	Member of the Editorial Board, Leukemia and Lymphoma
2/2005-12/2007	Associate-Editor, Hematological Oncology

Reviewer of manuscripts for various journals, including American Journal of Pathology, Annals of Oncology, Blood, Blood Advances, BMC Cancer, British Journal of Haematology, Cancer, Cancer Discovery, Clinical Cancer Research, Clinical Lymphoma, European Journal of Cancer, Haematologica, International Journal of Cancer, Journal of Pathology, Journal of Clinical Pathology, Lancet, Lancet Haematology, Leukemia, Leukemia and Lymphoma, Molecular Cancer Therapeutics.

Guest Editor for special issues for Annals of Lymphoma, European Journal of Medicinal Chemistry and Exploration of Targeted Anti-tumor Therapy.

Reviewer of national and international grant applications (including acting as member of the Scientific Evaluation Committee of the National Cancer Institute of France), and of abstracts submitted to international conferences.

## MEMBERSHIPS

American Association for Cancer Research (AACR); American Society of Clinical Oncology (ASCO); American Society of Hematology (ASH); American Society for Pharmacology and Experimental Therapeutics (ASPET); British Society of Haematology (BSH), European Society for Medical Oncology (ESMO); European Hematology Association (EHA); European Association for Cancer Research (EACR); European Organisation for Research and Treatment of Cancer (EORTC); Società Italiana di Cancerologia (SIC); Associazione Italiana di Oncologia Medica (AIOM); International Extranodal Lymphoma Study Group (IELSG); Swiss Group for Clinical Cancer Research (SAKK); NCCR RNA & Disease.

## PATENTS

- Sartori G, Cavalli A, Cascione L, Matkovic M, Bertoni F. Use of olfactory receptor OR13A1 ligands in the treatment of lymphomas. EP 4241766A1. Filing date: March 7th 2022. Applicant: Fondazione Per L'istituto Oncologico Di Ricerca (IOR) & Fondazione per l'Istituto di Ricerca in Biomedicina (IRB).
- Zimmerman J, Bertoni F, Arribas JA. Pharmaceutical combinations for treating cancer. WO2023285677A1. Filing Date: July 15, 2022. Application filed by SPEXIS AG.
- Mensah A, Spriano F, Pietra C, Lovati E, Bertoni F. Methods of using pracinostat in synergistic combinations to treat lymphoma. Application Number 63/091,741 Filing Date: October 14, 2020. Application filed by Helsinn.
- Gaudio E, Bertoni F, Pazzi N, Guala M. New compounds with enhanced anti-tumor effects. WO2019185117A1. Filing date: March 26<sup>th</sup> 2018. Applicant: Fondazione Per L'istituto Oncologico Di Ricerca (IOR).
- Zammarchi F, Bertoni F. Combination therapy. PCT/EP2019/073212, WO/2020/043878. Publication Date: March 5<sup>th</sup> 2020. Current Assignee ADC Therapeutics SA MedImmune Ltd.
- Zammarchi F, Bertoni F. Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent. PCT/EP2020/065879, WO2020249527A1. Publication Date: December 17th, 2020. Application filed by Adc Therapeutics Sa, Medimmune Limited.
- Zammarchi F, Bertoni F. Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent. WO2020249528A1. Publication Date: December 17th, 2020. Application filed by Adc Therapeutics Sa, Medimmune Limited.
- Binaschi M, Bigioni M, Merlino G, Simonelli C, Bertoni F, Pellacani A. M. Pharmaceuticals combinations comprising an anti-LY75 antibody. PCT/EP2018/055939. Publication Date: September 13<sup>th</sup> 2018. Filing date: March 9<sup>th</sup> 2018. Applicant: Berlin-Chemi AG.
- Marques CS, Busto N, Gaudio E, Bertoni F, Burke AJ. Novel N-(1,2,3-Triazolmethyl)Isatin and N-(1,2,3-Triazolmethyl)-3-Hydroxy-3-aryloxindoles with Cytotoxic and Anti-Tumor Activity. EP3400938B1/PTA 11006317. Filing date: 2018-04-18. Original Assignee: Universidad de Evora.
- Bertoni F, Romanelli A, Sloss C. Methods for improving anti-cd37 immunoconjugate therapy. PCT/IB2017/056841. WO2018083633A1. Priority date: 2016-11-02. Original Assignee: Debiopharm International, S.A.
- Riveiro ME, Raymond E, Bertoni F. Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds. WO2015189814 A1. Priority date: 2014-06-13. Publication date: 2015-12-17. Original Assignee: ONCOETHIX GmbH.
- Bertoni F, Inghirami G. Method of treating diffuse large B-cell lymphoma (DLBCL) using a BET-bromodomain inhibitor. PCT/EP2014/002164, WO2015018521 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.

- Bertoni F, Inghirami G. A BET-BRD inhibitor represents a novel agent for ALK positive anaplastic large cell lymphoma. WO2015018520 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.
- Bertoni F, Inghirami G. Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large B-cell lymphoma (DLBCL). PCT/EP2014/002163, WO2015018522 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.
- Bertoni F, Bonetti P. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2013/063313, WO2014001356 A1. Priority date: 2012-06-25. Publication date: 2015-04-29. Original Assignee: Oncoethix Sa.
- Bertoni F. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2015/069092, US15504722. Priority date: 2014-08-19. Publication date: 2015-08-19. Original Assignee: Original Assignee: ONCOETHIX GmbH.
- Bertoni F, Noel K. Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds. PCT/US2015/028835, WO2015168587 A1. Priority date: 2014-05-02. Publication date: Nov 5, 2015. Original Assignee: Oncoethix Sa.
- Simon G, Giannella-Borradori A, & Bertoni F. Roscovitine treatment of mantle cell lymphoma. PCT/GB2004/004700, WO2005044274 A1. Priority date: 2003-11-06. Publication date: 2005-05-19. Original Assignee: Cyclacel Limited.

## THESIS SUPERVISION

### PhD theses:

- "Identification and characterization of enhancer RNAs in marginal zone lymphoma and in mantle cell lymphoma" by Francesca Guidetti, USI, Lugano, Switzerland (**on-going**);
- "Genetic screening of enhancer RNAs to understand their causative biological role in refractory diffuse large B cell lymphoma" by Nicolas Munz, USI, Lugano, Switzerland (**on-going**);
- "Investigation of the role of mutated *TET2* in marginal zone lymphomas" by Fangwen Zhang, USI, Lugano, Switzerland (**2025**);
- "Preclinical evaluation of the ETS inhibitors YK-4-279 and TK-216 in lymphoma" by Filippo Spriano, UNIL, Lausanne, Switzerland, **2021**;
- "Role of ETS1 in the biology of ABC DLBCL" by Valdemar Priebe, UNIL, Lausanne, Switzerland, **2018**;
- "Epigenome as a therapeutic target for lymphomas" by Elena Bernasconi, UNIL, Lausanne, Switzerland, **2017**;
- "The contribution of genomic aberration to the pathogenesis of mature B-cell lymphomas" by Monica Testoni, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2014**;
- "Anaplastic large cell lymphoma: one or more entities?" by Michela Boi, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2013**;
- "Genomic profiling of diffuse large B-cell lymphomas" by Marta Scandurra, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2010**;
- "Stochastic methods in cancer research. Applications to genomics and angiogenesis" by Paola Rancoita, Universita' degli Studi di Milano, Dipartimento di Matematica, Milan, Italy;
- "Genomic profiling of B-cell lymphoid neoplasms" by Giulia Poretti, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2009**;

### Graduation theses:

- "Mechanisms of secondary resistance to PI3K/BCL2 inhibitors in marginal zone lymphoma", by Federica Fuzio, Corso di Laurea Magistrale in Biotecnologie del Farmaco, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2024**; "Olfactory receptor 13A1: a novel prospective therapeutic target in lymphoma malignancies", by Alessandro Ghiringhelli, Corso di Laurea Magistrale in Biotecnologie del Farmaco, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2024**; "Pre-clinical characterization of an antibody-drug conjugate (ADC) targeting CD19 in combination with targeted agents in cellular models of diffuse large B cell lymphoma (DLBCL)", by Eleonora Cannas, Corso di Laurea in Biomedical Sciences, Universita' degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese, Italy, **2022**; "Antitumoral activity of PIM inhibition in cellular models of diffuse large B-cell lymphoma", by Chiara Folloni, Corso di laurea in Scienze e Sicurezza Chimico-Tossicologiche dell'Ambiente, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2021**; "Preclinical evaluation of novel CREBBP/EP300 PROTACs as anti-lymphoma agents", by Giorgia Risi, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facoltà di Medicina Veterinaria, Milan, Italy, **2021**; "Antiproliferative activity induced by the dual pharmacological inhibition of ATR and PI3K in non-Hodgkin lymphoma cell lines", by Michele Mascia, Corso di laurea magistrale in Biotecnologie sanitarie mediche e veterinarie, Dipartimento di Veterinaria, Universita' di Sassari, Sassari Italy, **2020**; "Valutazione dell'attività antitumorale di inibitori del canale del potassio Kv1.3 in modelli cellulari di linfoma umano", by Marco Bernasconi, Corso di Laurea in Biotecnologie, Universita' degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese, Italy, **2020**; "Pre-clinical characterization of three novel antibody-drug conjugates in human lymphoma cell lines", by Lorenzo Scalise, Corso di Laurea in Biotecnologie Molecolari e Industriali, Universita' degli Studi dell'Insubria, Dipartimento di Scienze Teoriche e Applicate, Varese, Italy, **2019**; "Valutazione preclinica di un nuovo inibitore delle proteine BTK (farmaco 1) in singolo e in combinazione con altre molecole in modelli di linfoma umano", by Elisabetta Curti, Laurea in Scienze e tecnologie Biologiche, Universita' degli Studi dell'Insubria, Varese, Italy, **2018**; "Pre-clinical characterization of a new antibody-drug conjugate (ADC) in cellular models of diffuse large B-cell lymphoma (DLBCL)" by Francesca Guidetti, Laurea in Biologia Applicata alla Ricerca Laurea in Biologia Applicata alla Ricerca, Universita' degli Studi dell'Insubria, Varese, Italy, **2017**; "Valutazione preclinica di un nuovo inibitore delle proteine BTK (farmaco 1) in singolo e in combinazione con altre molecole in modelli di linfoma umano" by Elisabetta Curti, Laurea in Scienze e tecnologie Biologiche, Universita' degli Studi dell'Insubria, Varese, Italy, **2017**; "Novel BTK and PI3K-delta inhibitors show pre-clinical activity in combination in B-cell tumors", by Altea Targa, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facoltà di Medicina Veterinaria, Milan, Italy, **2015**; "A MEK1/2 inhibitor affects proliferation of human non-Hodgkin lymphoma cell lines", by Chiara Barassi, Laurea Magistrale in Biologia Sperimentale e Applicata, Universita' degli Studi di Pavia, Pavia, Italy, **2014**; "Pre-Clinical evaluation of a new anti-lymphoma agent", by Giovanna Panepinto, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facolta' di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2013**; "Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and TP53 pathway and differ from de-novo diffuse large B-cell lymphoma", by Marco Albonico, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facolta' di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2013**; "Valutazione del gene A20 come nuovo gene soppressore tumorale nei linfomi della zona marginale", by Silvana Branca, Laurea Specialistica in Biologia Applicata alla Ricerca Biomedica, Universita' degli Studi di

Milano, Facolta' di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2010**; "Evaluation of candidate cancer genes in diffuse large B-cell lymphomas" by Monica Testoni, Corso di Laurea in Biologia e Scienze Biologiche Universita' di Milano Bicocca, Milan, Italy, **2010**; "Tirosin chinasi Syk: nuovo target terapeutico in linfomi aggressivi di tipo B" by Sara Pesenti, Laurea Specialistica in Biotecnologie Industriali e Biocatalisi, Facolta' di Scienze Matematiche, Fisiche e Naturali, Universita' degli Studi dell'Insubria, Varese, Italy, **2007**

- **Diploma thesis:** "Tyrosine kinase Syk inhibitors in mantle cell lymphoma and in diffuse large B cell lymphomas: in vitro activity and mechanism of action" by Anna Sasso, ETH - Swiss Federal Institute of Technology Zurich, **2006**

## MAIN GRANTS

Title	Grant #	start	end	Amount given	Role
Overcoming B-cell lymphoma resistance to CD19-CAR T cells using combination therapies to enhance and sustain CD19 expression	Swiss National Science Foundation (SNSF) 310030_220070 / 1	2024	2027	CHF 602,885	Co-applicant
IELSG52: integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma	KFS-5778-02-2023	2023	2027	CHF 306,400	Co-applicant
First-in-class oncology therapeutics for hematological cancers targeting Wiskott Aldrich syndrome protein	Eurostars Project EI2829 HEMATO-WASP	2023	2025	CHF 332,104 (to FB)	Project partner
NCCR RNA & disease: The role of RNA biology in disease mechanisms (phase III)	Swiss National Science Foundation (SNSF) 51NF40_205601	2022	2026	CHF 1,463,913 (total)	Co-applicant
G protein-coupled receptors of the olfactory receptors' family provide novel therapeutic opportunities against lymphoma cells	Swiss Cancer Research KFS-5502-02-2022	08-2022	07-2025	CHF 341,400,828	main applicant
Evaluation of non-ATP competitive PI3K $\delta$ inhibition with IOA-244 in the treatment of lymphoma	Innosuisse 55179.1 IP-LS	08-2021	08-2023	CHF 596,828	academic research partner
Enhancer RNAs in B cell lymphomas	Swiss National Science Foundation (SNSF) 310030_197466	11-2020	10-2024	CHF 792,257	main applicant
Anti-L1CAM antibody therapy for rare diseases	Innosuisse 39947.1 IP-LS	11-2020	11-2022	CHF 683,987.84	academic research partner
Inhibitory effect of anti JAM-C antibodies in cell lines resistant to conventional pharmacological therapy	Innosuisse 48973.1 INNO-LS	09-2020	03-2021	CHF 15,000	academic research partner
Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors	SNSF NRP 78 Covid-19 #198265	10-2020	09-2022	CHF 1,098,174	co-applicant
The PI3K $\delta$ inhibitor IOA-244 as an immuno-regulator for the treatment of lymphoma	Innosuisse 43889.1 INNO-LS	05-2020	05-2021	CHF 15,000	academic research partner
Transcriptome analysis to improve the outcome prediction and to identify novel therapeutics targets in follicular lymphoma patients	Fondazione Ticinese per la Ricerca sul Cancro	06-2020	05-2021	CHF 80,000	main applicant
An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma	Oncosuisse KFS-4727-02-2019	08-2019	07-2022	CHF 360,305	main applicant
Genetic screening of enhancer RNAs to understand their causative biological role in refractory diffuse large B cell lymphoma	NCCR RNA & Disease	05-2020	04-2023	CHF 180,000	main applicant
Characterization of specific enhancer RNAs involved in ibrutinib resistance mechanism in marginal zone lymphoma	SNSF Sparks CRSK-3_190808	03-2020	02-2021	CHF 100,000	co-applicant
Ultra-conserved long non-coding RNAs in B-cell lymphoma	Oncosuisse KFS-4713-02-2019	08-2019	07-2021	CHF 180,600	co-applicant
Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas	Fondazione Ticinese per la Ricerca sul Cancro	06-2019	05-2020	CHF 60,000	main applicant
Multilayer model for personalized risk stratification of follicular lymphoma patients	Oncosuisse KFS-4395-02-2018	09-2018	08-2021	CHF 330,800	co-applicant
CA18238 - European transdisciplinary networking platform for marine biotechnology	COST (European Cooperation in Science and Technology)	10-2019	10-2023	-	Management Committee member
Surface expression of L1 cell adhesion molecule (L1CAM) in hematological malignancies	Innocheque 34266.1 INNO-LS	01-2019	03-2019	CHF 14,800	academic research partner
An implantable device to tailor treatment in patients with lymphoma	Fondazione Leonardo	04-2017	03-2019	CHF 280,000	main applicant
Novel small molecule targets FLI1 in lymphoma and T-ALL	Leukemia & Lymphoma Society #6521-17	10-2016	09-2019	USD 600,000	main applicant
Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations	SNSF 31003A_163232/1	10-2015	09-2018	CHF 429,800	main applicant
Characterization of FLI1 as an oncogene and therapeutic target in diffuse large B-cell lymphomas	Oncosuisse KLS-3580-02-2015	08-2015	07-2018	CHF 359,800	main applicant

An international phase III multicenter, randomized study with lenalidomide maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: Identification of DNA and methylation changes associated with the clinical outcome	Oncosuisse KLS-3636-02-2015	08-2015	07-2017	CHF 115,800	co-applicant
Identificazione di nuovi meccanismi patogenetici e nuove terapie in linfomi aggressivi pediatrici	Fondazione Gelu	10-2014	9-2017	CHF 650,000	main applicant
Development of a Center of Excellence in Lymphomas at IOSI	Nelia and Amadeus Barletta Foundation	10-2011	09-2014	CHF 1,500,000	main applicant
Functional analysis of altered transcriptional pathways in diffuse large B-cell lymphoma of the ABC subtype	SNSF Sinergia 147620	8-2013	7-2016	CHF 1,500,000	co-applicant
Steiner Trees for Functional Analysis in Cancer System Biology	SNSF 147138	4-2013	4-2016	CHF 153,900	co-applicant
Anaplastic Large Cell Lymphoma: One Or More Entities?	Anna Lisa Stiftung	4-2012	3-2014	CHF 100,000	main applicant
Functional characterization of an 11q24.3 gain contributing to the pathogenesis of diffuse large B cell lymphoma by blocking B-cell maturation	San Salvatore Foundation	12-2011	11-2013	CHF 231,000	main applicant
The methylome of splenic marginal zone lymphoma: an integration of epigenetic, genetic and clinical data	Jubiläumstiftung der Schweizerischen Lebensversicherungs- und Rentenanstalt für Volksgesundheit und medizinische Forschung (SwissLife)	04-2011	07-2014	CHF 60,000	main applicant
The methylome of splenic marginal zone lymphoma: an integration of epigenetic, genetic and clinical data	Fondazione Ticinese contro il Cancro	04-2011	04-2013	CHF 180,000	main applicant
Computational Identification Of Pathways And Genes Involved In Lymphoid Tumors: From DNA Copy Number To Expert System	"Ticino in Rete"- "Computational life sciences" network	08-2010	08-2012	CHF 250,000	main applicant
Genomic Alterations And Immunogenetics Of Richter's Syndrome, A Diffuse Large B-Cell Lymphoma Subtype With Very Poor Prognosis	Oncosuisse 02296-08-2008	02-2009	02-2011	CHF 150,000	main applicant
Anaplastic Large Cell Lymphoma: One Or More Entities?	Oncosuisse 02403-02-2009	08-2009	08-2011	CHF 150,000	main applicant
Computational Identification Of Pathways And Genes Involved In Lymphoid Tumors Starting From DNA Copy Number Analysis	"Ticino in Rete" "Computational life sciences" network	08-2008	08-2010	CHF 265,000	main applicant
Identification Of Prognostic Abnormalities By Genome-Wide DNA Profiling In B-Cell Chronic Lymphocytic Leukemia	Helmut Horten Stiftung	08-2008	08-2010	CHF 200,000	main applicant
Identification Of Prognostic Abnormalities By Genome-Wide DNA Profiling In B-Cell Chronic Lymphocytic Leukemia	San Salvatore Foundation	08-2008	08-2010	CHF 342,000	main applicant
A Bayesian Approach for Integrated Cancer Genome Profiling 2	SNSF 205320-121886	08-2008	09-2010	CHF 106,120	co-applicant
Genome Wide DNA Profiling As Outcome Predictor In Diffuse Large B Cell Lymphoma	Oncosuisse 1939-8-2006	02-2007	02-2009	CHF 226,800	main applicant
Extranodal, Nodal And Splenic Marginal Zone B-Cell Lymphomas: How Much Are They Related To Each Other?	Oncosuisse 02034-02-2007	08-2007	08-2010	CHF 157,800	main applicant
Evaluation Of The Tyrosine Kinase Syk As A Possible Therapeutic Target In Lymphomas	Oncosuisse 01835-02-2006	08-2006	08-2008	CHF 177,900	main applicant
A Bayesian Approach for Integrated Cancer Genome Profiling	SNSF 205321-112430	05-2005	04-2007	CHF 92,730	co-applicant
Cancer Genes Involved In Genetic Progression Of Germinal Centre B Cell Lymphomas	Oncosuisse 01517-02-2004	08-2004	08-2006	CHF 166,900	main applicant
Primary Central Nervous System Lymphoma: From An Improved Knowledge Of Its Peculiar Molecular And Biologic Feature Towards The Optimization Of Treatment	Oncosuisse Collaborative Cancer Research 01443-12-2003	08-2004	08-2006	CHF 450,000	main applicant
Genomic profiling on mantle cell lymphoma	SAKK - Swiss Group for Clinical Cancer Research	09-2003	09-2004	CHF 70,000	main applicant